A recent study has found that LGALS3 inhibitor can attenuate allodynia in a mouse model of Alzheimer’s disease (AD) (58), suggesting that sensory neuron-derived LGALS3 may promote allodynia through the microglial secretion of pro-nociceptive mediators. Here, LGALS3 is linked to Alzheimer disease.